Trial finds benefit of immunotherapy-chemotherapy combination in early-stage triple-negative breast cancer
Adding an immunotherapy agent to a three-drug chemotherapy regimen can improve the likelihood that early-stage triple-negative breast cancer will recede to undetectable levels
Source: BWH News - Category: Hospital Management Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Hospital Management | Immunotherapy